journal article·2017-04-03Open access

Preliminary studies for the development of intranasal nanoemulsion containing CNS agent: emphasizing the utilization of cut and weigh method

Amrish Kumar, Sunil Kumar Jain

Abstract

CONTEXT: The selection of excipients and preformulation strategy plays a vital role for the development of nanoemulsion, due to anatomical and physiological challenges posed by nasal cavity. OBJECTIVE: This attempt is focused on the selection and optimization of excipients for the development of a nanoemulsion system for intranasal delivery. MATERIALS AND METHODS: Excipients were selected on the basis of solubility of active drug, compatibility interactions and nasal irritancy. Surfactant and co-surfactant combination and their ratio were finalized on the basis of nanoemulsion region obtained from constructed phase diagrams with Capmul MCM as oil phase. A validated cut and weigh method was employed for the optimization of different phase diagrams with respect to nanoemulsion region. RESULTS AND DISCUSSION: The solubility of drug in Capmul MCM, Labrasol, and Transcutol-P was found to be superior with numeric values of 79.50 ± 1.68 mg/ml, 51.10 ± 1.39 mg/ml, and 36.60 ± 0.85 mg/ml, respectively. On the basis of phase diagram analysis, Labrasol and Transcutol-P in 3:1 ratio provides greater nanoemulsion region of 65.28 ± 0.18%. The validation of cut and weigh method revealed that there was no significant statistical difference (P > 0.05) with a %RSD value of 2.38 for intersheet variation. CONCLUSION: The results of validation studies for cut and weigh method suggests that it can be effectively used as an optimization method for the selection of nanoemulsion composition.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Advancements in Transdermal Drug Delivery · Inhalation and Respiratory Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (Central University), Bilaspur, Chhattisgarh, India

References (26)

Show source-provided references
1. 10.2174/15672011280352979210.2174/156720112803529792 ↗
2. 10.1016/j.ijpharm.2011.12.02810.1016/j.ijpharm.2011.12.028 ↗
3. 10.1016/0091-6749(83)90518-310.1016/0091-6749(83)90518-3 ↗
4. Gonjari ID · Drug Discov Ther · 2009 · 3 · 266
5. 10.1211/002235702253910.1211/0022357022539 ↗
6. 10.1124/jpet.301.1.39110.1124/jpet.301.1.391 ↗
7. 10.1166/jbn.2011.124010.1166/jbn.2011.1240 ↗
8. 10.1016/j.jconrel.2012.04.04410.1016/j.jconrel.2012.04.044 ↗
9. 10.3109/10717544.2014.92043110.3109/10717544.2014.920431 ↗
10. Kumar A · Int J ChemTech Res · 2009 · 1 · 941
11. 10.1016/j.ijpharm.2008.03.02910.1016/j.ijpharm.2008.03.029 ↗
12. Kumar P. · 2012
13. Kumar P · Asian J Pharm Tech · 2013 · 3 · 102
14. 10.1016/j.addr.2011.11.00210.1016/j.addr.2011.11.002 ↗
15. 10.1517/17425247.2011.58820410.1517/17425247.2011.588204 ↗
16. 10.2165/00126839-200708030-0000110.2165/00126839-200708030-00001 ↗
17. 10.1212/01.WNL.0000067993.60735.7710.1212/01.WNL.0000067993.60735.77 ↗
18. 10.2174/13892011280334175210.2174/138920112803341752 ↗
19. 10.18433/J3NC7910.18433/J3NC79 ↗
20. 10.2174/15701631179556386610.2174/157016311795563866 ↗
21. Risley DS · 2005 · 19 · 19310.1016/S0099-5428(08)60368-8 ↗
22. 10.2217/nnm.12.3810.2217/nnm.12.38 ↗
23. 10.1007/s13346-013-0133-310.1007/s13346-013-0133-3 ↗
24. 10.1007/s12272-012-0217-510.1007/s12272-012-0217-5 ↗
25. 10.1517/17425247.5.10.115910.1517/17425247.5.10.1159 ↗
26. 10.2174/15672051280010752810.2174/156720512800107528 ↗